Sakiris Spiro Kevin 4
4 · INTELLIGENT BIO SOLUTIONS INC. · Filed Mar 20, 2026
Research Summary
AI-generated summary of this filing
Intelligent Bio (INBS) CFO Spiro Sakiris Receives Award
What Happened
- Spiro K. Sakiris, Chief Financial Officer of Intelligent Bio Solutions, was granted two awards on March 18, 2026: 9,150 restricted shares and 21,350 restricted shares, for a total of 30,500 shares. Each grant shows an acquisition price of $0.00 (i.e., awarded shares, not purchased). The awards are subject to forfeiture until they vest.
Key Details
- Transaction date: March 18, 2026; Form 4 filed March 20, 2026 (timely within reporting window).
- Grant details:
- 9,150 restricted shares (time-based vesting over 48 months).
- 21,350 restricted shares (subject to combined performance-based and time-based vesting).
- Price: $0.00 per share (awarded shares, no cash exchanged).
- Shares owned after transaction: not reported in the provided excerpt of the Form 4.
- Footnotes of note:
- All amounts are presented post-1-for-10 reverse stock split effected Dec 15, 2025.
- The 2019 Long Term Incentive Plan governs these awards.
- The securities are held by Anest Holdings Pty Ltd as trustee for the S&T Sakiris Superannuation Fund; Mr. Sakiris is a director of that trustee.
Context
- These are restricted stock awards (compensation grants), not open-market purchases or sales. Such awards are routine executive compensation and become valuable only if and when vesting conditions are met; they do not indicate an immediate purchase or sale. The performance- and time-based vesting means future retention of the shares depends on meeting specified targets and remaining employed through vesting periods.
Insider Transaction Report
Form 4
Sakiris Spiro Kevin
Chief Financial Officer
Transactions
- Award
Common Stock
[F2][F1]2026-03-18+9,150→ 12,631 total - Award
Common Stock
[F3][F1]2026-03-18+21,350→ 33,981 total
Holdings
- 1,911(indirect: Held by Anest Holdings Pty Ltd)
Common Stock
[F1][F4]
Footnotes (4)
- [F1]On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.
- [F2]On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested.
- [F3]On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested.
- [F4]These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.
Signature
/s/ Spiro Sakiris|2026-03-19